Inositol Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Inositol dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Inositol.
Dosing Protocols
Beginner protocols — standard dosing for common indications:
For PCOS / insulin resistance / fertility support: Myo-inositol:D-chiro-inositol 40:1 combination, 2g myo-I + 50mg DCI, twice daily (total 4g myo-I + 100mg DCI per day). Take with or without food. Consistent daily dosing at approximately the same times. Expected timeline: some improvement in menstrual regularity and insulin markers within 1-2 months; peak effect on ovulation, androgen levels, and metabolic markers at 3-6 months; sustained benefit with continued use. Typical products: Inofolic Plus, Ovasitol, Theralogix Ovasitol, or similar 40:1 formulations. Always include folic acid 400 μg/day (often combined in PCOS products).
For gestational diabetes prevention (pregnancy, high-risk): Myo-inositol 2g orally twice daily + folic acid 400 μg/day, starting from first trimester (before 14 weeks gestation) and continuing through delivery. Indications for this protocol: family history of type 2 diabetes, pre-pregnancy BMI ≥25, previous gestational diabetes, PCOS history, or as recommended by obstetrician. Discuss with OB/midwife before starting. Expected benefit: ~50% reduction in GDM incidence (D'Anna 2013, 2015).
For general insulin sensitivity support (non-PCOS, no diabetes): Myo-inositol 2g twice daily or 1g four times daily with meals. Total 4g/day. Combines well with lifestyle interventions and other insulin sensitizers.
For mild anxiety or mood support: Myo-inositol 2-4g/day in divided doses (e.g., 2g morning + 2g evening). Note: this is below the therapeutic range for clinical panic disorder or OCD (which requires 12-18g/day). For mild sub-clinical anxiety, lower doses may provide modest benefit with excellent tolerability.
Starting and titration: Inositol is well-tolerated from initiation for most users at these doses. No ramp-up needed for standard PCOS/GDM doses. If starting higher psychiatric doses, consider ramping from 4g/day → 8g/day → 12g/day → target dose over 1-2 weeks to optimize GI tolerance.
Monitoring for PCOS use: Baseline (before starting): fasting insulin, HOMA-IR, total testosterone, free testosterone, SHBG, lipid panel, menstrual pattern tracking. Recheck at 3-6 months to assess response. Continue if improvement; reassess if no change (ensure adherence, consider alternative/adjunctive therapy).
Monitoring for GDM prevention: Standard obstetric glucose monitoring (early pregnancy glucose/HbA1c if high-risk; 24-28 week glucose tolerance test). No specific inositol-related monitoring needed beyond standard prenatal care.
Lifestyle foundations: Inositol works best as part of comprehensive approach. For PCOS: low-glycemic diet, regular aerobic + resistance exercise, stress management, adequate sleep. For GDM prevention: appropriate gestational weight gain, continued physical activity, balanced nutrition.
Duration: For PCOS, typically continued indefinitely for reproductive/metabolic support; some women pause during pregnancy (continuing instead the GDM-prevention dose) and resume post-partum. For GDM prevention, through delivery.
Intermediate protocols — psychiatric doses and IVF support:
For clinical panic disorder: Myo-inositol 12-18g/day, divided into 3-4 doses throughout the day (e.g., 4g four times daily, or 6g three times daily). Start lower (4g/day) and titrate over 1-2 weeks to target dose while monitoring GI tolerance. Take with food. Expected timeline: noticeable anxiolytic effect within 2-3 weeks; peak benefit at 4-6 weeks. If inadequate response after 6 weeks at 18g/day, reassess (possible alternate diagnosis, need for different/adjunctive treatment). Evidence: Benjamin 1995, Palatnik 2001 showing efficacy equivalent to fluvoxamine.
For OCD: Myo-inositol 18g/day, divided into 3-4 doses. Same titration approach. May be used as monotherapy or augmentation of SSRI. Expected timeline: measurable Y-BOCS improvement at 4-6 weeks; continued assessment at 3 months. Evidence: Fux 1996, 1999.
For major depression (monotherapy): Myo-inositol 12g/day divided into 3 doses. Expected timeline: effect over 2-4 weeks. Evidence: Levine 1995. If inadequate response at 6-8 weeks, add SSRI or pursue standard psychiatric care. Not a first-line treatment for moderate-to-severe depression where evidence for standard antidepressants is stronger.
For augmentation of SSRI in treatment-partial response: Myo-inositol 6-12g/day added to established SSRI. Evidence is mixed (Levine 1999 negative, Fux 1999 positive for OCD augmentation). Try for 4-6 weeks; continue if helpful, discontinue if no clear benefit.
For IVF pre-cycle support — women: Myo-inositol:DCI 40:1 combination (2g myo-I + 50mg DCI BID) starting 3 months before IVF cycle initiation and continuing through embryo transfer. Adjunctive: CoQ10 400-600mg/day (particularly for women over 35), vitamin D to sufficiency, folic acid 400-800 μg/day (usually in combination product). For poor responder profile: add DHEA 25-75mg/day per reproductive endocrinologist guidance.
For ovulation induction in PCOS (physician-directed): Myo-inositol 2-4g/day can be combined with clomiphene (Clomid) or letrozole (Femara) for ovulation induction — may enhance ovulatory response and reduce required dose of ovulation-induction agent. Physician-level prescribing.
For PCOS with significant hyperandrogenism (acne, hirsutism): Standard 40:1 combination PLUS consider: (1) spironolactone 50-100mg/day per physician; (2) oral contraceptive per physician; (3) zinc 30mg/day; (4) saw palmetto 320mg/day; (5) topical hair-removal strategies (laser, electrolysis). Inositol reduces androgen levels modestly but not to the degree of dedicated anti-androgen therapy — combination approach is often needed.
For hypomagnesemia and inositol co-therapy: Many PCOS patients have subclinical magnesium deficiency. Adding magnesium glycinate 200-400mg at bedtime improves sleep, mood, and insulin signaling synergistically with inositol.
Adjusting dosing for body weight: High-dose psychiatric protocols (12-18g) are somewhat weight-dependent. For subjects at <60kg, consider starting at 12g/day and assessing; for subjects >100kg, 18g/day may be more appropriate. PCOS/GDM doses do not require weight adjustment — 4g/day is the evidence-based dose across body weights.
Pregnancy continuation: Women on inositol for PCOS who become pregnant should typically continue myo-inositol (often switching to the 4g/day GDM-prevention protocol) throughout pregnancy. Discuss with obstetrician.
Advanced protocols and special contexts:
Very high-dose inositol for severe/refractory OCD: Some case series document use of myo-inositol 24-30g/day (above the standard 18g/day) for refractory OCD, sometimes with additional benefit but also more GI intolerance. Always requires psychiatrist supervision. Divided doses (6g four times daily) and with food optimize tolerance.
Inositol in bipolar disorder — cautious low-dose use: For bipolar patients with co-existing PCOS or insulin resistance, low-dose myo-inositol 2-4g/day is generally considered safe but warrants: (1) psychiatric supervision; (2) monitoring for mood destabilization; (3) awareness that lithium therapy may be attenuated at these doses. High-dose inositol (12-18g/day) is generally avoided in bipolar disorder outside of carefully monitored research contexts.
Inositol hexaphosphate (IP6, phytic acid) for metabolic and oncologic applications: IP6 is a chemically distinct compound from free inositol — it's inositol with six phosphate groups. IP6 has been studied for modest antioxidant effects, hepatoprotection, and possibly cancer-related effects (mineral binding, antiproliferative activities). IP6 is typically used at 1-4g/day. Note: IP6 is not the same as myo-inositol and should not be used interchangeably for PCOS, GDM, or psychiatric applications. IP6 for its own indications may be combined with inositol supplementation without interaction concern.
Inositol nicotinate (inositol hexanicotinate) for cholesterol: This is inositol + niacin — a "no-flush niacin" formulation that slowly releases niacin to reduce cholesterol with less flushing effect. Different indication from free inositol. Typical dosing 1-2g/day for lipid management. Not a substitute for free myo-inositol in other indications.
Scyllo-inositol for Alzheimer's disease — investigational: Scyllo-inositol is a distinct stereoisomer studied for anti-amyloid effects in Alzheimer's disease with generally negative clinical results (Salloway 2011 and subsequent). Not currently recommended outside research contexts.
Intravenous inositol for specific clinical applications: IV myo-inositol has been used in some clinical contexts (premature infant respiratory distress syndrome prevention, adjunctive uses in IVF) with specialized medical administration. Not typically accessible for outpatient use; mentioned for context.
Combining inositol with GLP-1 agonists for metabolic indications: With the rise of semaglutide (Ozempic, Wegovy) and related GLP-1 agonists, some PCOS and metabolic practitioners are combining these with inositol. No specific interaction but combined effects on weight loss and glucose control can be powerful; monitor for hypoglycemia and adjust as needed.
Inositol and polycystic kidney disease — caution: Despite the "polycystic" naming similarity, PKD is unrelated to PCOS. There is no established role for inositol in PKD, and the theoretical concerns are unclear. Not recommended outside specific research contexts.
Clinical monitoring for long-term users: (1) Baseline labs (for PCOS use): fasting insulin, HOMA-IR, total and free testosterone, SHBG, DHEAS, lipid panel, fasting glucose/HbA1c, thyroid function, vitamin D, B12. Menstrual pattern documentation. (2) 3-month recheck: insulin, androgens, menstrual pattern — adjust therapy if inadequate response. (3) Annual comprehensive reassessment: full labs, symptom and quality-of-life assessment, discussion of continued therapy vs alternatives. (4) Specific life transitions: pre-pregnancy counseling, pregnancy management, perimenopause management all warrant inositol-therapy review.
Research directions and emerging applications: Active research areas include inositol in autism spectrum disorders (behavioral and metabolic dimensions), inositol in chronic fatigue syndrome/ME-CFS, inositol in post-COVID syndromes, and specific inositol isomer ratios for personalized therapeutics in PCOS subtypes. These are research-stage and not yet established clinical applications.
Product quality considerations at advanced-use level: For chronic high-dose use (12-18g/day for psychiatric indications, daily IVF protocols), product quality matters more than for casual use. Prefer: (1) pharmaceutical-grade myo-inositol certified USP or equivalent; (2) established manufacturers with batch testing; (3) bulk powder sources that allow precise dose measurement and cost efficiency at high doses; (4) avoid products with unclear labeling, proprietary blends, or excessive excipients. Taste is slightly sweet — most users tolerate bulk powder mixed in water well.
Commonly Stacked With
Inositol stacks well with many complementary compounds given its favorable safety profile and low interaction potential. Stacks should be built around specific clinical goals.
For PCOS — the comprehensive metabolic-reproductive stack: (1) Myo-inositol:D-chiro-inositol 40:1 (Inofolic Plus or equivalent) at 2g myo-I + 50mg DCI BID — the evidence-based foundational combination. (2) Folic acid 400-800 μg/day — usually combined in PCOS/fertility inositol products; essential for any woman of reproductive potential. (3) Vitamin D 2,000-4,000 IU/day if deficient — vitamin D deficiency is common in PCOS and directly worsens insulin resistance and ovulatory dysfunction. (4) Metformin 500-1500mg/day — evidence-based for PCOS insulin resistance; combines well with inositol (different mechanisms, additive benefit). (5) N-acetylcysteine 600-1800mg/day — additional insulin-sensitizing and antioxidant effects. (6) Omega-3 fatty acids 2-3g/day — anti-inflammatory, modestly improves lipid profile. (7) Magnesium 200-400mg/day — cofactor for insulin signaling and supports sleep/mood often affected in PCOS. (8) Zinc 15-30mg/day if deficient — modest anti-androgenic effects.
For anxiety/OCD — psychiatric support stack: (1) Myo-inositol 12-18g/day split into 3-4 doses — the evidence-based therapeutic dose. (2) Magnesium glycinate or threonate 200-400mg/day — calming GABAergic effects, complements inositol anxiolysis. (3) L-theanine 200-400mg/day — additional GABAergic calming without sedation. (4) Omega-3 EPA 1-2g/day — modestly supports mood and anxiety. (5) Glycine 2-3g at bedtime — additional GABAergic calming, improves sleep. (6) If concurrent SSRI therapy: augmentation is possible but warrants psychiatrist guidance. (7) Ashwagandha 300-600mg/day — adaptogenic support for anxiety/stress.
For gestational diabetes prevention (pregnancy): (1) Myo-inositol 2g BID + folic acid 400 μg/day — the D'Anna-established protocol. (2) Prenatal multivitamin with appropriate iron. (3) Vitamin D 1,000-2,000 IU/day if not otherwise supplemented. (4) Omega-3 DHA 200-300mg/day — supports fetal neurodevelopment and may further support glycemic status. Avoid: most other "supplements" during pregnancy without specific obstetric guidance.
For IVF/fertility optimization — women: (1) Myo-inositol:DCI 40:1 (2g/50mg BID) + folic acid — evidence-based pre-IVF supplementation starting 3+ months before cycle. (2) CoQ10 200-600mg/day — supports oocyte mitochondrial function, particularly for women over 35. (3) Vitamin D to sufficiency. (4) Prenatal vitamin. (5) Discuss DHEA 25-75mg/day if poor ovarian responder — see DHEA entry.
For metabolic syndrome/prediabetes (non-PCOS): (1) Myo-inositol 2-4g/day alone or combination. (2) Berberine 500mg TID — strong insulin sensitizer, complements inositol. (3) Metformin per clinical indication. (4) Omega-3 2-3g/day. (5) Magnesium. Lifestyle (diet, exercise) remains foundational.
Combining inositol with psychiatric medications: (1) SSRIs (fluoxetine, sertraline, fluvoxamine, etc.) — can combine; Fux 1999 showed augmentation of fluvoxamine in SSRI-partial OCD responders. Monitor for serotonin-related side effects but no pharmacokinetic interaction. (2) SNRIs, atypical antidepressants — no known interaction. (3) Benzodiazepines — no interaction; inositol can supplement for anxiety while tapering. (4) Lithium — avoid high-dose inositol; theoretical counteraction of lithium's therapeutic effect. (5) Antipsychotics — no interaction. (6) Mood stabilizers in bipolar — caution with high-dose inositol.
Avoid combining or use with caution: (1) Lithium — as discussed, theoretical antagonism. (2) High-dose D-chiro-inositol alone in women with PCOS trying to conceive — the "DCI paradox" can worsen ovarian function; stick with myo-I alone or 40:1 combination. (3) Multiple inositol-labeled products simultaneously — some products contain inositol hexaphosphate (IP6), inositol nicotinate, or other forms; double-dosing by stacking different products may be inefficient or produce unclear effects. Use a single pharmaceutical-grade inositol source.
Synergy considerations: Inositol is notably non-interfering with most lifestyle interventions. Regular exercise enhances insulin sensitization beyond inositol alone. Low-glycemic diet complements inositol-based insulin sensitization in PCOS. Stress reduction (meditation, adequate sleep) enhances anxiolytic benefit. These foundational behaviors often produce more benefit than any supplement combination.
Side Effects & Safety
Contraindications
**Absolute contraindications**: **Known hypersensitivity** to inositol or product components — discontinue if allergic reaction occurs. **Relative contraindications requiring medical guidance**: **Bipolar disorder** — high-dose inositol (12-18g/day for psychiatric indications) should **not** be used without psychiatric supervision. Theoretical antagonism of lithium's mood-stabilizing mechanism (inositol depletion hypothesis of lithium action) and documented case reports of mania/hypomania induction. Low-dose (2-4g/day for PCOS) is generally acceptable in bipolar patients on stable mood stabilizer therapy but warrants monitoring. **Active lithium therapy** — high-dose inositol may attenuate lithium's therapeutic effect. Avoid or use with explicit psychiatrist guidance. **Type 1 or type 2 diabetes on insulin or sulfonylureas** — inositol's insulin-sensitizing effects may contribute to hypoglycemia in combination with insulin or insulin secretagogues. Monitor glucose closely during first 1-2 weeks of inositol initiation; adjust diabetes medications as needed. Not a strict contraindication but requires medication management. **Severe renal impairment (eGFR <30 mL/min)** — inositol is primarily renally excreted; accumulation is theoretical in severe CKD. Dose reduction may be prudent; discuss with nephrologist. **Pregnancy-specific considerations**: Inositol has an excellent safety record in pregnancy based on extensive GDM-prevention use. **No contraindication in pregnancy** at standard doses. High-dose psychiatric inositol (12-18g/day) has less pregnancy safety data — lower doses (2-4g/day) are strongly preferred during pregnancy unless psychiatrist specifically determines benefit outweighs risk. **Breastfeeding**: Inositol is naturally present in breast milk and in infant formula. Standard doses considered safe for breastfeeding. High-dose psychiatric use has limited lactation data but no known infant adverse effects. **Pediatric use**: Limited established indications. If used for pediatric conditions (autism spectrum, ADHD behavioral concerns), requires pediatric-specialist guidance. Not routinely recommended. **Situations warranting medical consultation before use**: **Any psychiatric medication use** — particularly lithium, anticonvulsant mood stabilizers, antipsychotics. Psychiatric context matters for inositol dosing. **Pregnancy or planning pregnancy with high-dose psychiatric inositol** — transition to lower doses pre-conception. **Any diabetes medication** — glucose monitoring guidance needed. **Surgery planned** — no specific inositol interaction with anesthesia; discontinuation not typically required but inform surgical team. **Kidney disease** — discuss dosing with nephrologist. **New mood symptoms** — any new manic, hypomanic, or psychotic symptoms on inositol warrant immediate medical evaluation and discontinuation. **Legal and regulatory status**: Inositol is a **dietary supplement** in the United States, Canada, Australia, and most countries — legally available without prescription at all standard doses. In some European countries (Italy particularly), pharmaceutical-grade inositol preparations are marketed with more formal regulatory oversight for PCOS and GDM prevention. Not a controlled substance; not restricted in sport (WADA permits inositol at any dose). **Quality variability concern**: Unlike prescription drugs with strict quality control, commercial inositol products vary substantially. Low-quality products may contain less active compound than labeled, may be contaminated, or may be mislabeled (e.g., inositol hexaphosphate sold as "inositol"). Use verified sources. **Not medical advice**: This content is educational. Specific use decisions — particularly in pregnancy, with psychiatric medications, with diabetes, or with other chronic health conditions — warrant physician-level guidance tailored to individual circumstances.
Additional Notes
Dosing by indication:
PCOS / fertility / IVF: Myo-inositol 2g + D-chiro-inositol 50mg, twice daily (total 4g myo-I + 100mg DCI daily). The 40:1 ratio is critical — avoid DCI-only products for PCOS fertility use. Continue indefinitely for ongoing management.
Gestational diabetes prevention: Myo-inositol 2g twice daily + folic acid 400 μg/day, from first trimester through delivery, in high-risk pregnancies.
General insulin sensitivity / metabolic syndrome: Myo-inositol 2-4g/day divided.
Panic disorder: Myo-inositol 12-18g/day divided into 3-4 doses.
OCD: Myo-inositol 18g/day divided into 3-4 doses.
Depression (monotherapy): Myo-inositol 12g/day divided.
Mild anxiety/mood support: Myo-inositol 2-4g/day divided.
Dosage forms: (1) Capsules — typically 500-1000mg each; convenient for lower doses but impractical at 12-18g levels (would require 12-36 capsules daily). (2) Powder — bulk myo-inositol powder is slightly sweet, dissolves readily in water or juice, and is the practical choice for high-dose use. One level teaspoon ≈ 2g. (3) Combination products (Inofolic Plus, Ovasitol) — usually provide 40:1 myo-I:DCI plus folic acid in pre-measured doses; convenient for PCOS use. (4) Flavored powders — some brands add flavors; check for added sweeteners (particularly avoid stevia additions if sensitive) and keep free of glucose/maltodextrin for diabetic use.
Timing considerations: (1) Food: inositol absorption is not significantly affected by food, but GI tolerance is often better with food at high doses. (2) Dose splitting: for doses ≥8g/day, dividing into 2-4 doses improves GI tolerance and maintains more stable plasma levels. (3) Morning vs. evening: no strong preference; consistent daily timing matters more than specific time. Some users prefer morning for any modest alerting effect of adequate hydration needed; evening dosing is fine. (4) With other medications: no timing-sensitive interactions with most medications. (5) Missed doses: skip and resume with next scheduled dose; do not double up. Inositol's long physiological half-life makes a single missed dose pharmacodynamically minor.
Pharmacokinetics summary: Oral bioavailability 75-90%; Tmax 2-4 hours; t½ 6-8 hours; Vd ~1 L/kg; minimal metabolism; primarily renal excretion. No significant dose adjustments needed for age, sex, or mild-moderate renal/hepatic impairment.
Dose adjustment for body weight: PCOS/GDM doses (2-4g/day) do not require weight adjustment. High-dose psychiatric protocols (12-18g) have some weight dependence — smaller subjects may achieve efficacy at 12g while larger subjects may need 18g. Titrate to response.
Adjustments for renal/hepatic impairment: No adjustment for mild-moderate impairment. In severe renal impairment (eGFR <30), consider dose reduction or reduced frequency given reduced clearance, though clinical impact has not been shown problematic.
Escalation/de-escalation: For high-dose psychiatric protocols, escalate from 4g → 8g → 12g → target over 1-2 weeks to optimize tolerance. For de-escalation, no taper needed — inositol can be stopped without rebound effects. Some users experience gradual return of baseline symptoms (anxiety, OCD) over days to weeks after stopping high-dose psychiatric use; reinstate if needed.
Concurrent diabetes medications: If on metformin, insulin, or sulfonylureas — inositol may enhance glycemic response. Monitor blood glucose during first 1-2 weeks of inositol initiation and have patient check glucose more frequently; adjust diabetes medications as needed in consultation with prescriber.
Frequently Asked Questions
What is the recommended Inositol dosage?
Dosage for Inositol varies by protocol. Consult a qualified healthcare provider.
How often should I take Inositol?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Inositol need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Inositol side effects?
**Inositol has one of the most favorable side effect profiles of any clinically effective compound**, reflecting its endogenous origin, lack of metabolism, and graduated physiological effects. However, some considerations warrant attention particularly at high therapeutic doses. **Gastrointestinal effects — the primary dose-limiting side effect**: At doses **above 12g/day** (particularly ≥18g/day used for OCD and panic disorder), **mild GI upset** is the most common side effect. Symptoms include **loose stools or diarrhea** (~5-10% of users at high doses), **nausea** (~3-5%), **abdominal bloating or gas** (~5-10%), and occasional **abdominal cramping**. These effects are generally dose-dependent and often improve with dose division (splitting total daily dose into 3-4 smaller doses throughout the day), taking with food, or gradual dose titration. At **standard doses for PCOS (2-4g/day)**, GI effects are rare (<2% incidence). At **GDM prevention doses in pregnancy (4g/day)**, GI tolerance is excellent — very few pregnant women report meaningful side effects. **Hypoglycemia risk — only relevant in specific contexts**: Inositol's insulin-sensitizing effects rarely produce clinical hypoglycemia in typical use but can contribute in specific contexts: (1) patients on **insulin** or **sulfonylureas** for type 2 diabetes — inositol may enhance glycemic response and warrant dose adjustment of antidiabetic medication; (2) patients with pre-existing **reactive hypoglycemia** may experience more pronounced post-meal glucose drops; (3) very high-dose inositol combined with fasting or skipped meals may contribute to symptomatic hypoglycemia in sensitive individuals. Standard PCOS and GDM prevention doses (2-4g/day) rarely cause hypoglycemia in healthy users. Monitor blood glucose if diabetic or prediabetic and adjust concurrent medications accordingly. **Bipolar disorder — caution regarding mania/hypomania**: As discussed in clinical studies, inositol supplementation at psychotropic doses (12-18g/day) has been associated with **mania or hypomania induction** in patients with bipolar disorder in case reports. This is theoretically consistent with the inositol depletion hypothesis of lithium's mechanism — increasing inositol might counteract lithium's stabilizing effect. **Anyone with bipolar disorder or prior hypomanic episodes should not use high-dose inositol without psychiatric supervision**. Standard PCOS/fertility doses (2-4g/day) are generally considered safer but still warrant caution. **Pregnancy and breastfeeding**: **Excellent safety data in pregnancy** based on extensive use for GDM prevention and fertility support. **D'Anna 2013, 2015** trials used myo-inositol 4g/day from first trimester through delivery in thousands of pregnancies with no safety signals. Congenital malformation rates, pregnancy outcomes, and infant development were comparable to placebo. Breastfeeding is similarly considered safe — inositol is present in breast milk naturally (including inositol added to infant formula as a nutrient) and supplemental doses have not been associated with adverse infant effects. **Drug interactions — minimal but notable**: Inositol has few clinically significant drug interactions given its lack of metabolism and absence of cytochrome P450 involvement. Considerations: (1) **Lithium** — theoretical interaction (inositol depletion hypothesis) — high-dose inositol may partially counteract lithium's mood-stabilizing effect; generally avoided in lithium-treated bipolar patients. (2) **Metformin** — complementary rather than interactive; combining them in PCOS is common and well-tolerated, with potential additive insulin-sensitizing benefit. (3) **Insulin/sulfonylureas** — potential additive hypoglycemic effect; monitor and adjust antidiabetic medication as needed. (4) **SSRIs** — additive serotonergic effects theoretically but clinically no meaningful interaction documented; combination sometimes used in refractory OCD/anxiety. (5) **Oral contraceptives** — no interaction documented. **Pediatric use**: Limited data. Inositol has been studied in pediatric populations for specific conditions (premature infant RDS support at IV doses, ADHD, autism spectrum behavioral symptoms) with generally favorable safety. Not routinely recommended for pediatric use without specific clinical indication and pediatric-level guidance. **Long-term safety**: Extensive long-term use data (years of 4g/day in women with PCOS, continuous use through multiple pregnancies for GDM prevention) show no accumulated toxicity, no organ system adverse effects, no increased cancer risk, and no cardiovascular safety signals. The endogenous nature of inositol and its renal excretion (rather than hepatic metabolism) contribute to this excellent long-term profile. **Allergic reactions**: **Rare but possible**. Reports of allergic reactions to inositol or to specific product formulations (usually reactions to excipients rather than inositol itself) exist but are infrequent. Discontinue if rash, swelling, or other allergic symptoms occur. **Kidney considerations**: Inositol is primarily renally excreted. In severe renal impairment (eGFR <30 mL/min), accumulation is theoretical but has not been shown to produce clinical problems in the limited studies. Dose reduction may be prudent in severe CKD. **Quality and product considerations**: Commercial inositol products vary widely in quality. **Pharmaceutical-grade inositol** (USP-certified) is preferred for therapeutic use. Some "inositol" products are actually inositol hexaphosphate (IP6, phytic acid) or inositol hexanicotinate (inositol + niacin) — these are **different compounds** with different effects. Check labels to ensure free myo-inositol (for PCOS, anxiety, GDM prevention) or the specified myo-I:DCI 40:1 combination. Avoid products with excessive excipients, fillers, or unclear labeling. **Expected vs concerning symptoms**: Expected early effects: mild GI adjustment during first week at high doses (usually resolves); gradual improvement in PCOS/insulin resistance markers over 1-3 months; psychiatric benefit in panic/OCD over 2-4 weeks at therapeutic doses. Concerning: any persistent diarrhea impairing function, any new psychiatric symptoms particularly mania/hypomania signs, any hypoglycemic symptoms in diabetic users, or any allergic-type reactions.
Where can I buy Inositol?
Visit our vendor directory to find trusted sources for Inositol.
Inositol Full Profile
Research data, mechanisms, and pricing
Interaction Checker
Check drug & compound interactions
Related Dosage Guides
All GuidesFree 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
